Paige.AI launches with $25M in funding, data license agreement with Memorial Sloan Kettering

Paige.AI, a New York City-based computational pathology startup focused on cancer diagnosis and treatment and backed by $25 million in Series A funding, launched Feb. 5.

Paige.AI uses artificial intelligence to help pathologists compile and interpret relevant patient data to guide diagnosis and treatment decisions. The startup's clinical decision support solutions will initially center on applications for breast and prostate cancers.

The company also signed a comprehensive license agreement with New York City-based Memorial Sloan Kettering Cancer Center to gain access to the hospital's library of 25 million pathology slides and intellectual property in the computational pathology field.

Under the agreement, Paige.AI will help Memorial Sloan Kettering digitize millions of archived pathology slides and leverage this data to train its clinical decision support algorithms.

"With computational pathology, pathologists can redirect their efforts toward more sophisticated tasks, such as integrating histologic findings with other diagnostic analyses," said David Klimstra, MD, pathology director of Paige.AI and chairman of the pathology department at Memorial Sloan Kettering.

More articles on artificial intelligence:
Microsoft launches Cortana Intelligence Institute to 'inject new thinking' into AI
Survey: Department heads more likely than clinicians to want AI in radiology
Oncology equipment, software vendor Elekta to sell IBM's Watson for Oncology in 2018: 4 things to know

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers